| Literature DB >> 28127437 |
Sascha David1, Kristina Thamm1, Bernhard M W Schmidt1, Christine S Falk2, Jan T Kielstein1.
Abstract
BACKGROUND: Sepsis and septic shock are major healthcare problems, affecting millions of individuals around the world each year. Pathophysiologically, septic multiple organ dysfunction (MOD) is a life-threatening condition caused by an overwhelming systemic inflammatory response of the host's organism to an infection. We experimentally tested if high circulating cytokine levels might increase vascular permeability-a critical hallmark of the disease-and if this phenomenon can be reversed by therapeutic cytokine removal (CytoSorb®) in an exemplary patient. CASEEntities:
Keywords: Cytokines; Endothelial permeability; Extracorporeal removal; Sepsis; Vascular leakage
Year: 2017 PMID: 28127437 PMCID: PMC5251288 DOI: 10.1186/s40560-017-0208-1
Source DB: PubMed Journal: J Intensive Care ISSN: 2052-0492
Clinical and laboratory findings
| Parameter | Pre | +12 h | +24 h (post) |
|---|---|---|---|
| Cytokine removal | |||
| Hemodynamics | |||
| Heart rate (bpm) | 107 | 120 | 111 |
| MAP (mmHg) | 58 | 62 | 70 |
| NA dose (μg/kg/min) | 0.40 | 0.11 | 0.09 |
| Respiration | |||
| PaO2/FiO2 | 65 | 68 | 120 |
| PEEP/ΔP | 15/20 | 15/19 | 15/18 |
| ECMO | |||
| Pump (rpm) | 3650 | 3650 | 3650 |
| Blood flow (L) | 3.6 | 3.72 | 3.54 |
| FiO2 (%) | 100 | 100 | 100 |
| Gas flow (L) | 4 | 4 | 4 |
| Renal function | |||
| Creatinine (μmol/L) | 242 | – | 70 |
| pH | 7.26 | 7.49 | 7.47 |
| HCO3− (mmol/L) | 18 | 20 | 21 |
| Lactate (mmol/L) | 3.1 | 1.8 | 0.9 |
| UO (mL/h) ±2 h | 15 | 0 | 0 |
| UF (mL) ±12 h | 0 | −1200 | −4900 |
| Lab parameters | |||
| CRP (mg/L) | 222 | 149 | 187 |
| PCT (μg/L) | 81.2 | 60.4 | 34.4 |
| INR | 1.45 | – | 1.18 |
| WBC (1/nL) | 41.4 | – | 23.6 |
| PLT (1/nL) | 92 | – | 41 |
| Hb (g/dL) | 12.1 | – | 10.5 |
NA noradrenaline, MAP mean arterial pressure, PEEP positive end-expiratory pressure, P pressure, UO urine output, UF ultrafitration, CRP C-reactive protein, PCT procalcitonine, INR international normalized ration, WBC white blood cells, PLT platelets, Hb hemoglobin
Cytokine, chemokine, and growth factor removal 24 h after Cytosorb® treatment
| Parameter | Pre | Post | Rel. reduction (%) |
|---|---|---|---|
| Cytokine removal (pg/mL) | |||
| IL-1a | 643.9 | 76 | −88.2 |
| IL-6 | 89.9 | 14.0 | −84.4 |
| CXCL8 (IL-8) | 68.4 | 19.9 | −70.9 |
| IL-9 | 12.9 | 7.2 | −44.2 |
| IL-10 | 80.7 | 40.0 | −49.6 |
| IL-13 | 7.1 | 10.8 | +51.5 |
| FGF | 48.1 | 21.4 | −55.6 |
| GM-CSF | 57.5 | 38.6 | −32.9 |
| CXCL10 (IP-10) | 24,723.7 | 2827.5 | −88.6 |
| CCL2 (MCP-1) | 375.0 | 45.9 | −87.8 |
| CCL4 (MIP-1b) | 125.4 | 39.2 | −68.8 |
| PDGF-bb | 719.8 | 245.3 | −65.9 |
| RANTES | 3912.2 | 1326.1 | −66.1 |
| TNF-a | 59.2 | 24.8 | −58.1 |
| VEGF | 63.7 | 19.5 | −69.5 |
IL interleukin, CXCL C-X-C motif chemokine, FGF fibroblast growth factor, GM-CSF granulocyte-macrophage colony-stimulating factor, IP interferon gamma produced protein, CCL C-C motif ligand, MIP macrophage inflammatory proteins, MCP monocyte chemotactic protein, PDGF platelet-derived growth factor, RANTES regulated on activation, normal T cell expressed and secreted, TNF tumor necrosis factor, VEGF vascular endothelial growth factor
Fig. 1Endothelial phenotype with respect to barrier function. Fluorescence immunocytochemistry staining for vascular endothelial (VE)-cadherin (green), F-actin (red), was performed on confluent human umbilical vein endothelial cells (HUVECs) as described before [5]. Cells were treated for 30 min with media supplemented with 5% serum from an individual with septic shock before (2nd row) and after cytokine removal (3rd row); 5% healthy human serum served as a control (1st row). Scale bar 10 μm
Fig. 2Transendothelial resistance (TER) of HUVECs treated with septic serum. Normalized transendothelial electrical resistance (TER) was longitudinally measured in real time in human umbilical vein endothelial cells (HUVECs) with an electric cell-substrate impedance sensing (ECIS) device. HUVECs were then challenged with either septic serum before cytokine removal (bold line) or with serum from the same patient 24 h after cytokine removal (dotted line). TER normalization refers to the start point of the experiment for each condition (i.e., 5 min before septic serum incubation)